These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36068392)

  • 1. Drugs acting on the renin-angiotensin-aldosterone system (RAAS) and deaths of COVID-19 patients: a systematic review and meta-analysis of observational studies.
    Sharma R; Kumar A; Majeed J; Thakur AK; Aggarwal G
    Egypt Heart J; 2022 Sep; 74(1):64. PubMed ID: 36068392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 and the Angiotensin-Converting Enzyme 2 Receptor: Angiotensin-Converting Enzyme Inhibitor/Angiotensin 2 Receptor Blocker Utilization and a Shift Towards the Renin-Angiotensin-Aldosterone System Classical Pathway.
    Felber R; New W; Riskin SI
    Cureus; 2024 Mar; 16(3):e55563. PubMed ID: 38576704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
    Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
    J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
    Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
    Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Interplay Between the Immune System, the Renin-Angiotensin-Aldosterone System (RAAS), and RAAS Inhibitors May Modulate the Outcome of COVID-19: A Systematic Review.
    Naveed H; Elshafeey A; Al-Ali D; Janjua E; Nauman A; Kawas H; Kaul R; Saed Aldien A; Elshazly MB; Zakaria D
    J Clin Pharmacol; 2021 Aug; 61(8):987-1000. PubMed ID: 33635546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of renin-angiotensin-aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study.
    Sato K; White N; Fanning JP; Obonyo N; Yamashita MH; Appadurai V; Ciullo A; May M; Worku ET; Helms L; Ohshimo S; Juzar DA; Suen JY; Bassi GL; Fraser JF; Arora RC;
    BMC Cardiovasc Disord; 2022 Mar; 22(1):123. PubMed ID: 35321649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Severity.
    Alhaddad MJ; Almulaify MS; Alshabib AA; Alwesaibi AA; Alkhameys MA; Alsenan ZK; Alsheef HJ; Alsaghirat MA; Almomtan MS; Alshakhs MN
    Cureus; 2022 Mar; 14(3):e22903. PubMed ID: 35399441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis.
    Liu Q; Fu W; Zhu CJ; Ding ZH; Dong BB; Sun BQ; Chen RC
    BMC Infect Dis; 2023 Jan; 23(1):53. PubMed ID: 36694122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
    Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
    JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between renin angiotensin aldosterone system blockers and future osteoporotic fractures in a hypertensive population - A population-based cohort study in Taiwan.
    Kao YT; Huang CY; Fang YA; Liu JC
    Int J Cardiol; 2020 Apr; 305():147-153. PubMed ID: 31955975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined use of renin-angiotensin-aldosterone system-acting agents: a cross-sectional study.
    Farcas A; Leucuta D; Bucsa C; Mogosan C; Dumitrascu D
    Int J Clin Pharm; 2016 Dec; 38(6):1390-1397. PubMed ID: 27677980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Association between Chronic Use of Renin-Angiotensin-Aldosterone System Blockers and in-Hospital Adverse Events among COVID-19 Patients with Hypertension.
    Cetinkal G; Kocas BB; Ser OS; Kilci H; Yildiz SS; Ozcan SN; Verdi Y; Altinay M; Kilickesmez K
    Sisli Etfal Hastan Tip Bul; 2020; 54(4):399-404. PubMed ID: 33364877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients.
    Genet B; Vidal JS; Cohen A; Boully C; Beunardeau M; Marine Harlé L; Gonçalves A; Boudali Y; Hernandorena I; Bailly H; Lenoir H; Piccoli M; Chahwakilian A; Kermanach L; de Jong L; Duron E; Girerd X; Hanon O
    J Am Med Dir Assoc; 2020 Nov; 21(11):1539-1545. PubMed ID: 33138935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis.
    Lo KB; Bhargav R; Salacup G; Pelayo J; Albano J; McCullough PA; Rangaswami J
    Expert Rev Cardiovasc Ther; 2020 Dec; 18(12):919-930. PubMed ID: 32945216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research.
    Loader J; Taylor FC; Lampa E; Sundström J
    J Am Heart Assoc; 2022 Jun; 11(11):e025289. PubMed ID: 35624081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis.
    Chu C; Zeng S; Hasan AA; Hocher CF; Krämer BK; Hocher B
    Br J Clin Pharmacol; 2021 Jun; 87(6):2475-2492. PubMed ID: 33217033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
    Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
    Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.
    Ferrario CM
    Life Sci; 2010 Feb; 86(9-10):289-99. PubMed ID: 19958778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Renin-Angiotensin-Aldosterone System Inhibitors on Short-Term Mortality After Sepsis: A Population-Based Cohort Study.
    Hsu WT; Galm BP; Schrank G; Hsu TC; Lee SH; Park JY; Lee CC
    Hypertension; 2020 Feb; 75(2):483-491. PubMed ID: 31838905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Renin-Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials.
    Yin J; Wang C; Song X; Li X; Miao M
    Am J Hypertens; 2022 May; 35(5):462-469. PubMed ID: 35512430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.